

SC3041

Mise à disposition d'un outil de veille technologique et stratégique

Case 1

Which companies develops in vitro medical devices and drugs for Beta-thalassemia (at large, including all subtypes of the disease):

- Name of said companies and in vitro medical devices and drugs
- All drugs /in vitro medical devices (disease screening, companion diagnostic, and diagnostic) in development or marketed
- Classification by type of product: small molecule vs biotherapy (antibody, ATMPs, etc.), gene or cellular therapies
- Classification by development stage : preclinical → marketed
- Names of CDMO co-development partner for production for clinical trials
- Other

For start-up or young biotechs which may be working on this indication, how much funds these companies have raised for these therapies + information such as:

- Sustainability, financial stability (through public information such as press releases, congress presentation)
- Merge and acquisition
- Deals

Incidence and/or prevalence of patients with Beta-thalassemia, in US, Europe, World

Case 2

Which companies develop ATMP solutions based on iPS cells for regenerative medicine, especially cardiac diseases, and their CDMO partners :

- Name of said companies and relevant contacts (if available)
- Name of ATMP solutions under development, their classification within bioproducts (cell or gene therapy, biologicals), if there is any gene editing stage
- The stage of development (R&D, preclinical, tox studies) or clinical stages of ATMP solutions
- The source of iPS cells (if available)
- The targeted therapeutic area
- If the development and the GMP manufacturing are/ will be performed in house, if not : the name of the CDMO's partner
- Companies expectations and next steps